The Evolution of T-cell Dysfunction in AML – Tailored Antibody-based Immunotherapy to Increase Response Rate and Overcome Innate and Adaptive Resistance

• Applicants: Professor Dr. Karl-Peter Hopfner; Professorin Dr. Marion Subklewe
• Subject Area: Hematology, Oncology ; Biochemistry ; Immunology
• Term: from 2020 to 2023
• Project identifier: Deutsche Forschungsgemeinschaft (DFG) - Project number 451580403

Treatment of AML by allogeneic stem cell transplantation is mediated by T cells but is hampered by a high mortality rate. We find that T-cell function is modulated through progressively evolving changes in phenotype and function of AML. Our goal is to unravel changes in T-cell responses and develop multi-specific anti¬body derivatives (msADs), tailored to interfere with immune checkpoint molecules in specific geno- and phenotype of AML subtypes.

• DFG Programme: Research Grants